Skip to content

Brenden Samuel Rabinovitch

Department of Clinical Research, Numinus Toronto, Toronto, ON, Canada.

2 papers in the library · 16 citations · publishing 2023-2024

Papers

Psychedelics, epilepsy, and seizures: a review

Frontiers in Pharmacology January 12, 2024 Ninon Freidel, Liliane Kreuder, Brenden Samuel Rabinovitch et al. 11 citations

Clinical trials of psychedelics for neurological and psychiatric disorders have systematically excluded people with past or current seizures, despite a lack of evidence that supervised psychedelic use causes or worsens seizures. No clinical trial or preclinical seizure model has shown that psychedelics induce seizures. This review presents cases where individuals experienced either seizures or seizure remission after psychedelic use, with the overall trend indicating safety in controlled clinical settings. The authors propose future research directions to include this population.

Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.

Neurotrauma reports January 1, 2023 Stephanie Karzon Abrams, Brenden Samuel Rabinovitch, Rayyan Zafar et al. 5 citations

People with spinal cord injury (SCI) who use classical serotonergic psychedelics such as psilocybin and LSD often experience intense muscle spasms, sweating, and tremors, a phenomenon not previously described in academic literature. These symptoms resemble a peripherally dominant serotonin syndrome-like clinical picture and can interfere with any beneficial effects. The authors propose a theoretical framework for this hypersensitivity and call for awareness to guide harm reduction, informed consent, and development of protocols that allow safe use of psychedelic-assisted therapy in this population.